David Westenberg
Stock Analyst at Piper Sandler
(3.71)
# 736
Out of 4,876 analysts
169
Total ratings
47.57%
Success rate
7.97%
Average return
Main Sectors:
Stocks Rated by David Westenberg
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEM Tempus AI | Maintains: Neutral | $55 → $70 | $68.34 | +2.43% | 4 | May 15, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Neutral | $2 → $1.25 | $1.29 | -3.10% | 8 | May 15, 2025 | |
| NTRA Natera | Maintains: Overweight | $205 → $210 | $168.17 | +24.87% | 15 | May 15, 2025 | |
| ILMN Illumina | Maintains: Overweight | $190 → $185 | $94.16 | +96.47% | 16 | May 15, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $205 → $210 | $155.79 | +34.80% | 14 | May 12, 2025 | |
| LH Labcorp Holdings | Maintains: Neutral | $260 → $280 | $256.98 | +8.96% | 4 | May 6, 2025 | |
| NEO NeoGenomics | Maintains: Overweight | $18 → $12 | $7.16 | +67.60% | 9 | May 6, 2025 | |
| GH Guardant Health | Maintains: Overweight | $50 → $60 | $50.03 | +19.93% | 9 | May 6, 2025 | |
| FLGT Fulgent Genetics | Maintains: Neutral | $16 → $23 | $19.60 | +17.35% | 8 | May 6, 2025 | |
| ADPT Adaptive Biotechnologies | Maintains: Overweight | $11 → $13 | $12.16 | +6.91% | 13 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $180 → $200 | $177.06 | +12.96% | 7 | Apr 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6.4 → $5 | $4.79 | +4.38% | 12 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $2.4 → $1.65 | $1.33 | +24.06% | 8 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $16 → $12 | $14.30 | -16.08% | 9 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $8.5 → $8 | $3.55 | +125.35% | 9 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $70 | $51.81 | +35.11% | 10 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $435 → $510 | $527.78 | -3.37% | 10 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $11.70 | - | 1 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $28.70 | - | 2 | Jan 4, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $56.24 | - | 1 | Nov 21, 2017 |
Tempus AI
May 15, 2025
Maintains: Neutral
Price Target: $55 → $70
Current: $68.34
Upside: +2.43%
Pacific Biosciences of California
May 15, 2025
Maintains: Neutral
Price Target: $2 → $1.25
Current: $1.29
Upside: -3.10%
Natera
May 15, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $168.17
Upside: +24.87%
Illumina
May 15, 2025
Maintains: Overweight
Price Target: $190 → $185
Current: $94.16
Upside: +96.47%
Zoetis
May 12, 2025
Maintains: Overweight
Price Target: $205 → $210
Current: $155.79
Upside: +34.80%
Labcorp Holdings
May 6, 2025
Maintains: Neutral
Price Target: $260 → $280
Current: $256.98
Upside: +8.96%
NeoGenomics
May 6, 2025
Maintains: Overweight
Price Target: $18 → $12
Current: $7.16
Upside: +67.60%
Guardant Health
May 6, 2025
Maintains: Overweight
Price Target: $50 → $60
Current: $50.03
Upside: +19.93%
Fulgent Genetics
May 6, 2025
Maintains: Neutral
Price Target: $16 → $23
Current: $19.60
Upside: +17.35%
Adaptive Biotechnologies
May 6, 2025
Maintains: Overweight
Price Target: $11 → $13
Current: $12.16
Upside: +6.91%
Apr 28, 2025
Maintains: Neutral
Price Target: $180 → $200
Current: $177.06
Upside: +12.96%
Apr 22, 2025
Maintains: Neutral
Price Target: $6.4 → $5
Current: $4.79
Upside: +4.38%
Apr 14, 2025
Maintains: Neutral
Price Target: $2.4 → $1.65
Current: $1.33
Upside: +24.06%
Mar 6, 2025
Maintains: Neutral
Price Target: $16 → $12
Current: $14.30
Upside: -16.08%
Mar 4, 2025
Maintains: Overweight
Price Target: $8.5 → $8
Current: $3.55
Upside: +125.35%
Feb 26, 2025
Maintains: Overweight
Price Target: $75 → $70
Current: $51.81
Upside: +35.11%
Feb 10, 2025
Maintains: Neutral
Price Target: $435 → $510
Current: $527.78
Upside: -3.37%
Mar 5, 2020
Initiates: Buy
Price Target: n/a
Current: $11.70
Upside: -
Jan 4, 2018
Upgrades: Buy
Price Target: n/a
Current: $28.70
Upside: -
Nov 21, 2017
Initiates: Neutral
Price Target: n/a
Current: $56.24
Upside: -